AKT1 (AKT Serine/Threonine Kinase 1; E17K) is a hotspot mutation that activates PI3K/AKT signaling across cancers and exists in NSCLC subsets; early clinical data with AKT inhibitors (e.g., capivasertib). Here, AKT1 is linked to non-small cell lung carcinoma.